Dear Foregen Supporters,
Welcome back to our most recent newsletter. We have some important updates for you, and an overview of the best parts of January so far.
What’s Happened Since Last Time
- We have the primer written by Eric Cunningham which summarizes and explains the major sections and points of our recent publication in Journal of Tissue Engineering.
- In less than two months Foregen will also be attending SXSW and we’re working on getting our booth ready. We look forward to speaking with more people about what we’ve done and the future of our work, along with new connections we can make.
- For the month of January so far we reached a total of $4,147 in donations, which helps us move forward with the next parts of our mission! Be sure to inform other activists, friends and family about Foregen and the science we’re pursuing to one day help provide genital integrity to men around the world. Our overall total to date is $407,546 - Let’s keep it up.
Tell Me Something Interesting
- This article describes the recent breakthrough where scientists used stem cells “to grow perfect human blood vessels as organoids in a petri dish for the first time. The breakthrough engineering technology, outlined in a new study published today in Nature, dramatically advances research of vascular diseases like diabetes.”
- An article describes how new research at Boston University “from the Growth Factor Mechanobiology Lab of Michael Albro, a College of Engineering assistant professor of mechanical engineering, biomedical engineering and materials science and engineering, has shown promise in developing a method to grow the tissue without the typical instability or imperfections associated with engineered cartilage.”
Volunteer for Foregen
If you are interested in any of the following positions, please click on them to read more and apply:
Thanks for reading, and stay tuned for our next newsletter. If you’d like more frequent updates, please head over to our blog, or visit one of our social media accounts – the links are at the bottom of this newsletter.
The Foregen Team